country. The state should recognise the growing importance of regenerative medicine and accept its responsibility to play an active role in determining how this need can best be satisfied in the South African context. The state should recognise that the private sector could play an important role in establishing stem cell banks and may share the financial burden.

To ensure good policy and decision making it is therefore suggested that the state should take the initiative and convene a suitable forum where the national policy on establishing UCB banks can be discussed. Ways in which a public UCB bank can possibly be funded, and whether regenerative medicine should be regarded as a health priority, should be considered. The respective roles of the state and the private sector in establishing and funding a public cord blood bank, possibly on a fee-for-service basis, could be debated.

Such a facility would benefit South African patients and address moral and ethical issues related to inequitable medical services, and the disparate donor/recipient availability of stem cells in this country.

Vernon J Louw
Division of Clinical Haematology
Department of Internal Medicine
Faculty of Health Sciences
University of the Free State

Anthon du P Heyns
Department of Haematology and Cell Biology
Faculty of Health Sciences
University of the Free State

References
15. National Health Act, 2003 (Act No. 61 of 2003), Section 3(e).

A Pan-African Clinical Trials Registry for the specific needs of triallists on the continent

Clinical trials provide the best evidence for which health care interventions work, which do not, and which may be harmful. Ideally we aim to base our clinical practice on the results from well-conducted trials. For us to be able to do so, all trial reports must be available in the public domain and accurately reflect the methods and the results of clinical trials.

Trial reports may not be available publicly due to publication bias – the tendency for positive and significant trial results to be published preferentially and for negative or neutral trial results to be refused, or withheld from, publication. Prospective trial registration arose out of the need to reduce the effects of publication bias and to encourage greater public disclosure, particularly in industry-led trials. Prospective registration encourages triallists to record the aim, objectives, outcomes and planned analysis of their trial on a clinical trial register before enrolling the first patient. After successful registration the trial is allocated a unique identification number.

Clinical trial registration has become an important part of the clinical trial process since the Ministerial Summit on Health Research called on the World Health Organization (WHO) in 2004 to establish ‘a network of international clinical trial registers to ensure a single point of access and the unambiguous identification of trials’. In 2005 this call was endorsed by the 58th World Health Assembly and supported by the International Committee of Medical Journal Editors (ICMJE), who updated their statement so that only trials registered on WHO-endorsed primary registers would be...
published in participating journals (www.who.int/ictrp/).
A WHO primary registry must comprise the WHO’s 20-item
minimum dataset in which trial registrants publicly disclose
specific trial information. This standardised information is
then regularly uploaded on to the WHO International Clinical
Trials Portal (www.who.int/trialsearch/), a search engine that
enables searching for trials according to specific characteristics
such as by intervention or location.

In South Africa, the necessity to register trials is legislated
through Section 11(r) in the National Health Act of 2004
(www.ufs.ac.za). The South African National Clinical Trials
Registry (SANCTR) (www.sanctr.gov.za) is administered by
the National Department of Health and is named as the venue
through which to fulfil this obligation in the South African
Good Clinical Practice Guidelines, 2nd edition (2006), in section
1.5.2 (www.doh.gov.za/nbrec/norms/gcp.pdf). Currently, the
SANCTR does not fulfil the ICJME mandate for clinical trials
registration because it is not a WHO-endorsed primary registry.
We would advise South African triallists to also register their
trial on another WHO-recognised primary registry to ensure
that they may be considered for publication in ICJME journals.

To provide opportunities for local registration, the South
African Cochrane Centre (SACC), based at the Medical
Research Council, established the Pan-African Clinical Trials
Registry (PACTR) in 2007. The PACTR (www.pactr.org) is
funded by the European and Developing Countries Clinical
Trial Partnership and provides a platform for prospective
registration of all clinical trials in Africa. On 25 September
2009, the PACTR was officially launched as a WHO-endorsed
primary register in Abuja, Nigeria, the only such register in
Africa.

**Trial work evolving in Africa**

African triallists face challenges to registration such as limited,
unreliable and costly Internet access. The PACTR seeks to
provide feasible ways of overcoming this by allowing triallists
to register by postal mail or facsimile in addition to online and
via e-mail. Since the PACTR was first established in 2007, 42
applications for registration have been received with 6 of these
sent by e-mail to be completed by the Project Manager. We also
provide dedicated telephonic and e-mail support to registrants.

The number of trial applications has increased progressively
over time. In 2008 there were only 12 applications, whereas
2009 saw 26 new applications, with most registrations
following immediately after the official announcement of
WHO primary register status in Abuja. As word of the registry
spreads, representation among African nations is increasing on
the PACTR. PACTR data reveal 10 single-centre trials taking
place, in South Africa (4), Egypt (2), Kenya (1), Tanzania (1) The
Gambia (1) and Uganda (1); 7 multi-centre trials have sites in
12 African countries, including Burkina Faso, Ethiopia, Gabon,
Guinea Bissau, Mozambique, Nigeria, Rwanda, South Africa,
Tanzania, Uganda, Zambia and Zimbabwe, and 1 non-African
country, India (Fig. 1). Registered trials cover research on a
range of diseases: HIV/AIDS (7), tuberculosis (4), co-morbid
TB and HIV (3), malaria (1), birthing (1), hyperkalaemia (1) and
prostate surgery (1).

**Conclusion**

Clinical trial registration does not replace the need for
legislation and should not function as an ethics watch-group,
but a registry can promote and encourage compliance with
regulatory and legal requirements. If African countries
participate actively in the PACTR, their prospectively
registered trials will be traceable and accessible in the future.
As more trials are registered, the PACTR will provide a
comprehensive, searchable, free repository of African trials,
ensuring that African trial activity is adequately represented
globally.

Registration and information on registered trials is free of
charge and easy to access. To learn more about PACTR or to
register a trial, please visit our website www.pactr.org.

The project is funded by the European and Developing
Countries Clinical Trials Partnership.

**Amber Abrams**
Pan-African Clinical Trials Registry Project Manager
South African Cochrane Centre
Medical Research Council, Cape Town

**Nandi Siegfried**
Co-director and Senior Specialist Scientist
South African Cochrane Centre
Medical Research Council, Cape Town

**Corresponding author:** A Abrams (amber.abrams@mrc.ac.za)